Oncology and diabetes dominated cross-border out-licensing deals by South Korean pharma/biotech companies over the 2015 to 2017 period, largely in line with the trends in global pharma, but the total number and value of deals in the Asian country declined over the period despite the domestic industry's ongoing efforts to seek overseas partners and enter international markets.
The number of cross-border out-licensing deals by Korean companies fell to nine in 2017 from 14 in 2015, largely affected...







